Sort
64,565 grants matching “drug discovery”
Cyclic Peptides to Treat Cocaine Use Disorder
$945,491Jane V Aldrich · University Of Florida · UG3 · FY2023 · NS
Active Immunization for Treating Methamphetamine Abuse
$945,482S. Michael Owens · Univ Of Arkansas For Med Scis · U01 · FY2009 · DA
Development of novel proteins synthesis inhibitors for MDR tuberculosis
$945,212Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2012 · AI
Clinical development of emetine hydrochloride for the treatment of viral infection
$945,175Mark Henderson · National Center For Advancing Translational Sciences · ZIA · FY2022 · TR
Attacking stress tolerance in cancer
$945,158David A Cheresh · University Of California, San Diego · R35 · FY2020 · CA
Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds
$945,014Andrea Ghetti · Anabios Corporation · R44 · FY2016 · TR
Defining and Controlling Airway Disease
$945,000Michael Jay Holtzman · Washington University · R35 · FY2025 · HL
Defining and Controlling Airway Disease
$945,000Michael Jay Holtzman · Washington University · R35 · FY2023 · HL
Defining and Controlling Airway Disease
$945,000Michael Jay Holtzman · Washington University · R35 · FY2021 · HL
Defining and Controlling Airway Disease
$945,000Michael Jay Holtzman · Washington University · R35 · FY2022 · HL
Preclinical Pulmonary Fibrosis, an opportune rare disease cohort
$944,445David Albert Schwartz · University Of Colorado Denver · UG3 · FY2021 · HL
Assessing the effects of peripheral immune activation on the NVU following TBI using a vascularized and perfused human blood/BBB model
$944,440Dritan Agalliu · Columbia University Health Sciences · R61 · FY2022 · HL
Discovery of Chemical Probes and Therapeutic Leads, Phase 2
$944,312Joseph M Fox · University Of Delaware · P20 · FY2023 · GM
Fox COBRE Phase II Admin Core
$944,312Joseph M Fox · University Of Delaware · P20 · FY2023 · GM
Single Cell Multiplex Screening of Protein Families
$944,279Novasite Pharmaceuticals, Inc. · R01 · FY2004 · EB
New Ways of Targeting K-Ras
$944,270Frank Patrick McCormick · University Of California, San Francisco · R35 · FY2018 · CA
New Ways of Targeting K-Ras
$944,270Frank Patrick McCormick · University Of California, San Francisco · R35 · FY2020 · CA
Helping to End Addiction Long-term (HEAL): Induced Pluripotent Stem Cell (iPSC)-Derived Cell Types for Pain, Addiction and Overdose
$944,124Ilyas Singec · National Center For Advancing Translational Sciences · ZIA · FY2022 · TR
DNA Polymerase IIIe, A New Antibiotic Target
$944,079Glsynthesis, Inc. · R44 · FY2005 · AI
Institute for Biomedical and Health Disparities Research
$944,076Texas Southern University · G12 · FY2005 · RR
Lead Optimization and Preclinical Development of a small molecule inhibitor of M. avium KasA
$944,067David Alland · Hackensack University Medical Center · U19 · FY2025 · AI
Systems Biology based Proteogenomic Translator for Cancer Marker Discovery towards Precision Medicine
$944,067Pei Wang · Icahn School Of Medicine At Mount Sinai · U24 · FY2016 · CA
Develop, Optimize and Commercialize UltraMarathonRT: A new enzyme for unbiased transcriptomic and epitranscriptomic characterization of RNAs regardless of length or composition.
$944,054Li-Tao Guo · Rnaconnect Inc · R44 · FY2025 · GM
Novel oxadiazols for the treatment of drug-resistant gram-positive bacteria
$944,017Mayland F Chang · University Of Notre Dame · R01 · FY2013 · AI
Defining and Controlling Airway Disease
$944,000Michael Jay Holtzman · Washington University · R35 · FY2020 · HL